Liquid biopsies are beginning to fill a major niche in molecular diagnostics and the number of commercial companies offering liquid biopsy analysis is continuously increasing. Experts estimate that using DNA blood tests for cancer screening will be a $10-20 billion a year market by 2020. Companies are investing hundreds of millions of dollars to develop the innovative technologies required to test for liquid biopsies. Ultimately, a liquid biopsy may provide a less-expensive and less-invasive way to monitor patients throughout treatment, and large molecular diagnostic companies see this investment as high risk and even higher reward. As clinicians, it will be important to weigh the risks and benefits discussed earlier in this review, and compare and contrast the available liquid biopsy assays available. A non-inclusive list of commercially available liquid biopsy assays is listed here:
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Thank you for participating in this module. Click below to download the certificate.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.